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Metallic and permanent bone implants expose trauma patients to recurring fractures and infections 
even after years of implantation. Metallic implants also predispose for stress shielding phenomenon and 
fibrous capsule formation driving the research to find more biocompatible solutions for implant 
materials and construction. Bioactive materials such as bioactive glasses have proven to be effective at 
repairing large bone defects, cure and prevent bone infections during the healing process, and they are 
completely biodegradable.  
Our goal is to create novel biodegradable composite implants which are comprised of polymer matrices 
reinforced with bioactive glass fibres. With such composite, it could be possible to create a load bearing 
and biodegradable implant that would also be osteoinductive and antimicrobial with customizable 
degradation time.  
For this, we have chosen 3 different types of bioactive glass compositions 1-06, 13-93, and 18-06 that 
represent fast, medium, and slow bioactivity profiles, respectively, according to the literature. We 
prepared the glasses, pulled them into fibers and performed a dissolution test and SEM analysis to assess 
the bioactivity profile of the glasses in fiber form. The secondary goal was to evaluate the usability of 
these fibers as structural components.  
The results from the dissolution test in simulated body fluid and SEM analysis confirmed that the 1-06 
glass fibers were bioactive. The 13-93 and 18-06 fibers did not respond to SBF, start leeching ions or 
form a calcium phosphate layer. However, the 13-93 blocks, that were used as the positive control, did 
have a stronger response to the SBF than the 1-06. This suggests that the 1-06 fibers might represent a 
medium bioactivity profile instead of fast. These results might also mean that the 13-93 and 18-06 fibers 
were not immersed long enough for them to dissolute and they might still represent the suggested 
bioactivity profiles. Although, the glass composition of the fibers was altered during the fiber pulling 
process and the fibers had different composition than intended. 
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1.1 The Introduction and the Structure of Bioactive Glasses 
The issue of foreign body reactions and rejection to the first-generation biomaterials, such as metallic 
or plastic materials, in the late 1960s was presented to Larry Hench1 and he became fascinated by the 
idea of creating a more biocompatible biomaterial. He hypothesised that if the material could form 
hydrated calcium phosphate, also known as hydroxyapatite, it might be more biocompatible and not be 
rejected by the human body1. This hypothesis lead to the discovery and development of the second-
generation biomaterials, namely bioactive glasses (BG), and ultimately to the invention of 45S5 
Bioglass® in the early 1970s2.  
The classic BGs, such as the Bioglass®, are based on the traditional soda-lime-glass composition. They 
compose of the oxides of silicate (SiO2), sodium (Na2O), calcium (CaO), and phosphate (P2O5). The main 
structure of the BGs consists of Si-O backbone where silicon cations are connected by oxygen anions. 
Each silicon forms a tetrahedra with 4 oxygen atoms and each oxygen is linked to two silicon atoms 
connecting the tetrahedra together creating an organized interconnected network3,4. These oxygens 
connecting the silicon atoms are called the bridging oxygens (BOs). This kind of structure network is 
naturally occurring for example in quartz stone which is really hard and chemically stable mineral with 
low bioavailability of silicon5. For this reason, modifier oxygens (MOs), such as Na2O and CaO, are added 
to the matrix to break up the dense and highly interconnected structure. These MOs from Si-O-Na+ and 
Si-O-Ca2+ bonds and create non-bridging oxygens (NBOs) which break the interconnective chain 
creating more disorder and loosen the structure3,4. 
The main factor that separates vitreous silica from rock-like minerals is the amorphous structure which 
is created by the loose interconnectivity of the silicate structure. This kind of disruption is essential for 
any kind of reactivity for a glass, but to achieve bioactivity, the ratio of BO to NBO and the structural 
components must also be balanced. For example in Bioglass®, Hench used 45 m-% SiO2, 24.5 m-% CaO, 
24.5 m-% Na2O, and 6 m-% P2O5, hence the name 45S5 – 45% Si and 5:1 molar ratio of calcium to 
phosphate. To achieve reactivity, it is important that liquids such as water can penetrate the glass 
surface and get into the structure. As the glass starts to dissolve, the ionic composition needs to be 
suitable for the calcium phosphate formation so that the biological reactions can take place. The general 
rule is that by decreasing the interconnectivity of the silicate network the reactivity of the BG increases 
and by increasing the interconnectivity the less reactive it becomes1,6,7. This can be described by the Qn-
state of the silicate atoms where the n (n=0–4) equals the number of bridging oxygens connected to the 
silicon tetrahedra. Most bioactive glasses are largely dominant in the Q2 species and secondary in Q3 
species due to the MOs disrupting the interconnectivity3,4,8. The overall interconnectivity can be 
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presented by calculating the average number for the Qn species which translates to the network 
connectivity (NC) value. According to Mathew et al., NC of 2.1 to 2.6 is the range for optimal bioactivity 
for BGs8, and while moving closer to 3 the bioactivity gradually decreases reaching the upper limit of 
bioactivity at around 2.98,9. However, the loss of bioactivity is more accountable to the increase of Q4 
species rather than the Q3s. Mathew et al., estimated that over 10% Q4 species would result in the loss 
of bioactivity. Usually the characteristics of the glass are modified by changing the ratios of the silicon 
and the MOs or by changing the surface area of the glass1,4,10,11. Addition of sodium or calcium, removal 
of silicon, increased porosity or smaller particle size increase the reactivity, while the opposite actions 
or the addition of multivalent cations, such as aluminium, manganese, or titanium, decrease the 
reactivity1,4,7,11,12.   
Phosphate, however, appears in the glass mostly as orthophosphate lacking any covalent bond to the 
silicon backbone3,4,8. The lack of covalent bonds makes orthophosphate readily available and easily 
dissolvable from the glass matrix. Orthophosphate content directly increases the bioactivity of the glass 
when the electronegative charges are balanced with Na+ and Ca2+ ions8,13. When the balance is not met, 
the phosphate starts to form BO bonds to the silicon which actually increases the NC and decreases the 
bioactivity of the glass, since the covalent bonds need to be hydrolysed before the phosphate can be 
released8,13. The phosphate molecules rarely form more than one BO bond but this is enough to tightly 
bound them to the structure causing them to no longer contribute to the overall bioactivity the same 
way as orthophosphate8,13.  
Since the early days, more complex bioactive glasses have been made and now bioactive glass has 
become an umbrella term for a variety of biocompatible glasses that can bond to bone and soft tissue2. 
The third-generation biomaterials utilize more precisely engineered bioactive materials that aim to 
cause a specific cellular response at a genetic level, and combines them with medical grade polymers 
creating composites that better mimic the biological environment of the human body1,14. Some third-
generation biomaterials use bioresorbable polymers which could provide a fully biodegradable 
biomaterial, but so far, they have been limited to non-load-bearing applications. The next step for the 
fourth-generation biomaterials have been speculated to include manipulation of the electrical systems 
of the cells with the aim of creating even more accurately engineered biological solutions that would 
improve the integration, better mimic the natural environment of the body, and lower the failure rates 
of the bioactive implants14.  
Currently, The US Food and Drug Administration (FDA) has approved Bioglass® 45S5 and Bonalive® 
S53P4 BGs for clinical use as a bone substitute material. Most of the clinical applications utilize the BGs 
as particulate, usually as such, mixed with a viscous substrate to create a putty, or embedded in a non-
resorbable composite matrix when load bearing capabilities are required. These applications can be 
used to fill in cavities in bones after for example a bone tumour removal or for acceleration of bone 
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regeneration after traumatic events. These applications show good treatment response in both non-load 
bearing and load bearing conditions15–18. However, the non-resorbable composite materials still may 
need to be surgically removed after their purpose has been fulfilled requiring more hospital visits and 
risking a post-surgery infection. This leaves an unmet medical need for load bearing bioresorbable 
materials that are naturally removed from the body over time.  
 
1.2 The Mechanism of Action and the Cellular Responses 
The bone forming effects of bioactive glasses can be separated into two main events – the formation of 
a calcium-phosphate layer and the promotion of the beneficial cellular reactions1,12.  When in contact 
with aqueous solutions like the human extracellular fluid, the water molecules penetrate to the glass, 
interact with the Na+ and Ca2+ ions, and detach them from the matrix. This means that the BG starts to 
dissolve as soon as it comes to contact with the aqueous solutions. The water molecules donate their 
hydroxide group and release NaOH and Ca(OH)2 from the matrix in exchange for the H+ ions. NaOH and 
Ca(OH)2 readily ionize in the water releasing the OH- and raising the local pH. This rapid exchange of 
ions and increase in pH creates an alkaline environment in which also the basic structure of the glass 
starts to break. The OH- ions start to hydrolyse the Si–O–Si bonds and cause the release of silicon from 
the network12. The silicon cations react with the hydroxide anions and start forming silicic acids 
(Si(OH)x-4-x) which create a layer of silica gel on the surface of the glass. The released silicon then 
condenses and repolymerises on the surface of the glass forming a scaffold where the released but also 
endogenous calcium and phosphate can start to precipitate. The CaO-P2O5 layer eventually absorbs 
carbonates and hydroxyls from the extracellular fluid and crystallise into hydroxyapatite (HA)1,12. This 
is a key event for the bone regeneration since HA is the most common mineral in bone and can act as a 
foundation for the bone cells to attach. Osteoblasts and osteogenic precursor cells can attach themselves 
to the crystallized calcium phosphate/HA layer and start their natural actions for bone regeneration.  
The other key event for bone regeneration is the promotion of osteogenic differentiation and 
proliferation through activation of cellular mechanisms19. The cellular reactions are initiated by the 
dissolution products of BGs, mainly by the increase in local Ca and Si ion concentrations20–24.  
Ca2+ ions are the most important for osteoblast differentiation, proliferation, and bone mineralization24–
28. Maeno et al. tested the cellular response of primary mouse osteoblast monolayer and 3D cultures to 
differing Ca2+ ion concentrations, and the results showed increased proliferation at 2-6 mM Ca2+ 
concentration and increased matrix mineralization and differentiation at slightly higher concentrations 
of 6-10 mM24. Whereas Narita et al., cultured murine osteoblasts in the presence of CA(OH)2 and 
discovered that the calcium ions caused prolonged activation of p38 and JNK which have an important 
role in bone mineralization27. Calcium acts on the surface of the bone precursor cells through a calcium-
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sensing receptor(CaSR) which activates from high extracellular calcium concentration28,29. Dvorak et al.  
demonstrated CaSR-related cellular responses in multiple osteoblast cell lines in the presence of 
extracellular calcium28. In their study, the CaSR excitation resulted in the activation of mitogen activated 
ERK 1/2 pathway and Akt, and the inhibition of GSK3β which affect osteoblast proliferation, the 
activation of a transcription factor Cbfa1 and its downstream proteins osteocalcin and osteopontin 
which are key effectors in osteoblast differentiation and mineralization, and the activation of alkaline 
phosphatase which has a role in bone mineralization. 
Silicon is considered an essential micronutrient for bone development and healthy bone metabolism 
with an effect on osteoblast proliferation and metabolic activity5,30. In the study by Rettiff et al., 
orthosilicic acid (Si(OH)4) promotes collagen type-1 production in human osteoblasts, and has an impact 
on osteoblastic differentiation shown by the increased alkaline phosphatase and osteocalcin activity31. 
However, they discussed that whether silicon is the direct contributor to the commitment of osteoblastic 
differentiation and ECM mineralization remains unclear, but regardless silicon undoubtedly has a 
positive effect for bone formation and metabolic activity of osteoblasts. Furthermore, silicon has 
inhibitory effects on bone resorption through induced secretion of osteoprotegerin and subsequent 
inhibition of RANKL activity which leads to reduced osteoclasts maturation and activation32,33, indirectly 
enhancing the regenerative processes.  
Additionally, while having a bigger impact for the bone regeneration through calcium phosphate 
crystallization, inorganic phosphate has an effect through ERK1/2 pathway which activates the 
transcription factor Fra-134. Julien et al. suggested that Fra-1 has a role in the activation of matrix Gla 
protein (MGP) which is an important regulator in bone mineralization34. In their study, they discussed 
that MGP overexpressing mice show improper bone mineralization, and that Fra-1 overexpressed mice 
develop osteosclerosis while Fra-1 deficient mice develop osteopenia34. Through this pathway, 
phosphate released from the BG can regulate the cell metabolism of osteoblasts and promote proper 
mineralization of the bone.  
These dissolution products also upregulate multiple other factors either directly or indirectly. These 
include transcription factors, cell-cycle regulators, signal transduction pathways, growth factors, DNA 
repair proteins, apoptosis regulators, ECM related proteins, and differentiation markers1,20–23,26. Xynos 
et al. identified over 100 upregulated mRNA species in human osteoblasts when cultured with in the 
presence of 45S5 BG, and of those mRNA species, 60 were recognized to have increased 2 to 7-fold in 
contrast to the control22. The upregulation of mRNA species indicate activation of genes, and in this case, 
they were found to be specifically beneficial for osteoblast differentiation, proliferation, and viability. 
Furthermore, the genes synergise well with each other enhancing and complementing simultaneous and 
consecutive signalling pathways and cellular processes.  
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According to Xynos et al.22, some of the upregulated transcription factors are osteoblast specific, such as 
RCL growth related c-myc, c-jun and fra-1. These transcription factors are responsible for transitioning 
the osteoblast precursor cells from the stationary G0 phase into the active G1 phase which prepares the 
cell for replication. Furthermore, three different cell cycle regulators which allow the progenitor cells to 
pass specific cell cycle checkpoints and lead to DNA replication and eventually mitosis were also 
upregulated1,21,23. Cyclin D1, which is responsible for the crucial transition from G1 phase to DNA 
synthesis phase (S phase), was up regulated by 400%. Two other cyclins, cyclin K and CDKN1A, which 
are responsible for early stages of mitosis were upregulated by 200 and 350%, respectively.  
The DNA synthesis and replication processes during the S phase are fragile and prone to error due to 
the sheer amount of actions happening during the duplication and recombination. Therefore, different 
DNA repair proteins are present during the replication phase to facilitate error correction during the  
recombination and complete DNA replication. Xynos et al. identified multiple upregulated DNA 
synthesis, repair, and recombination protein coding genes in their study22. DNA exclusion repair protein, 
mutL protein homolog, and HMG-1 are examples of the upregulated proteins that are ensuring complete 
DNA synthesis. 
While it is important that the cell pass the required cell cycle phases and differentiate into osteoblasts, 
it is equally important to clean out the cells that are incapable of dividing and only leave the cells that 
lead to bone growth. Upkeeping of the incapable cells is draining energy and nutrients from the 
differentiated cells, and therefore it is highly beneficial to eliminate the incapable cell by apoptosis to 
recycle nutrients and proteins from these cells. The upregulated genes by the BG dissolution products 
include multiple apoptosis regulators, such as DAD1, calpain, and deoxyribonuclease II, which are 
responsible for elimination of the incapable cells21,23.  
Additionally, different growth factors and signal transduction pathway inducers can promote the 
osteogenic progenitor cells to differentiate and osteoblasts to grow and proliferate. Some of these potent 
growth factors such as insulin-like growth factor II (IGFII), vascular endothelial growth factor (VEGF), 
macrophage colony stimulating factor (MCSF), and bone-derived growth factor are upregulated by 
BG21,22,26. Signal transduction pathway inducers, such as MAPKAP kinase 2, are also upregulated further 
more proving the synergistic effect of the BG dissolution products have on bone regeneration22.  
Another good marker for matured and viable osteoblasts is that the cells start to produce collagen and 
other ECM compounds. The upregulated cell differentiation markers and ECM related protein genes are 
proving that the cells undergo changes which lead to bone formation. Osteoblasts cannot produce actual 
bone nodules, so they need to specialise and differentiate into osteocytes. According to Xynos et al., the 
most upregulated gene is the cell surface antigen CD44 which is an osteocyte specific marker22. The 7-
fold increase in CD44 expression implies that the osteoblasts are further differentiating into mature 
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osteocytes that are capable of forming bone nodules. In addition, the ECM production related genes such 
as matrix-metalloproteinase 2 and 14, TIMP2, and bone proteoglycan 2 precursor are upregulated 
which proves that the cells are active and producing matrix related components21–23. In conclusion, the 
BG does not only provide a biological scaffold for bone regeneration but also actively promotes cell 
maturation and bone formation through cell signalling and gene activation. While it is not clear if the BG 
dissolution products are specifically activating all of these genes or are some of them results of normal 
cellular downstream signalling cascades which have been activated by BG, it is certain that BGs guide 
bone cells towards proliferation and regeneration.  
 
1.3 The Antibacterial Properties 
The most prevalent challenge associated with the treatment of bone cavities is the management of 
infections. Since bone defects or cavities often lack sufficient blood supply because of damaged blood 
vessels, the defects are often immunocompromised and filled with coagulated blood and extracellular 
fluid which offer ideal conditions for bacteria to thrive and spread. This makes BGs a very feasible 
treatment option in the clinical setting since it is also antimicrobial18,35–39. Munukka et al. tested the 
antimicrobiality of several BGs on 29 clinically important aerobic bacteria and all the BGs had 
bactericidal or bacteriostatic effects on all or most of the bacteria35 with some variation depending on 
the glass composition, bacterial species, and time of exposure. However, the bactericidal effect was 
proven on both gram-negative and gram-positive species. One of the glasses they had used, 13-93, is 
also being used in the present study as the positive control glass. In the tested in vitro environment, it 
demonstrated bactericidal effects on all but the most resistant strains and at least bacteriostatic of 
growth inhibiting effect on all of the bacterial strains.  
The antimicrobiality of BGs is fully physiological and it is caused by the drastic changes in the local 
microenvironment. The dissolution products  from the BG locally increase the pH and osmotic pressure 
and make the area around the glass unsustainable for the bacteria and other microbes. The high osmotic 
pressure drives water out of the bacterial cell causing them to shrink and dry due to the reverse osmosis. 
The shrinkage can cause development of holes to their cell membrane which leads the to the collapse 
and death of the cell36. The high pH causes distractions to the membrane potential and therefore cellular 
activity and metabolism decreasing their viability. 
The environmental changes are caused by the dissolution of the mineral oxides and ionization of water 
molecules. By the mechanism explained in the part 1.2, the water molecules act as a nucleophile and 
break the bonds between the alkanes and the oxygen that connects them to silicon by donating the  
proton to the connecting oxygen and releasing NaOH or Ca(OH)2. These hydroxides readily ionize in 
aqueous environment releasing the hydroxide which directly increases the surrounding pH. 
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Simultaneously, the released sodium, calcium, and phosphate locally increase the osmotic pressure in 
the area since these ions are also naturally present in the ECF.  
Bioactive glasses are also able to target bacteria which have developed a protective biofilm37,40. Biofilms 
are often formed on abiotic prostheses and the surrounding tissues around it by infectious bacteria that 
have adhered on a surface. These bacteria start secreting extracellular polymeric slime and extracellular 
DNA which aggregate and form a protective polysaccharide layer, all while the initial bacteria grow and 
start forming a highly organized multi-layered bacterial colony of several different species which can 
send clusters to infect other sites41. Biofilms cause issues for infection treatment because the antibiotics 
and immune cells cannot affect the bacteria from under the protective layer of polysaccarides41,42. 
Bioactive glasses can damage the biofilm and therefore expose the bacteria36,37,40. This can also be useful 
for example in combination therapy which involves antibiotics and the bioactive glass. In combination 
therapy, antibiotics can target the healthy tissue around the bone defect while the bioactive glass has its 
effect inside the defect. This is further improved by the BG’s ability to induce angiogenesis via 
upregulation of VEGF in fibroblasts21,43, since the better vascularity will provide better inflow of 
antibiotics and immune cells to the defect area.  
 
1.4 The Processability of Bioactive Glasses 
The BG’s ability to bond to bone and create incredibly synergistic cellular responses is what makes BG 
so efficient in repairing large bone defects like cavities18,44 and allows substantial bone reformation 
operations15. However, the usability of BGs in the clinical setting is currently largely limited by the poor 
processability of the glasses1,11,12,45–47. The commercially available BG products mostly utilise BGs as 
particulate which limits their usage to non-load bearing applications such as fillers for bone cavities. 
Clinically usable BG applications should fulfil certain qualities to be suitable for various situations. 
Clinical biomaterials for bone healing should present a high number of interconnected pores to allow 
bone cells and fluids to flow freely throughout the material, but also have structural properties 
mimicking that of damaged area so it can serve as a proper supporting scaffold for the natural healing 
of the bone1,12,48,49. The dissolution rate should also be aligned with the speed of the tissue regeneration 
so that the material keeps its shape until the new tissues can take the load. These are the fundamental 
qualities that a BG application should have, but for it to be also commercially feasible, ease of 
manufacturing and replicability should also be considered.  
The issue with the traditional soda-lime glasses, such as 45S5 and S53P5, is that they crystallize easily 
at high temperatures which limits their usability to monoliths and particulate1,4,11,46,47,50. Because of the 
amorphous and loose structure of the glasses, they have a tendency to crystallise at certain temperature 
which is called the crystallisation temperature (Tc)8,50–52. At the Tc, the glass structure finds the lowest 
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state of the energy expenditure which causes densification of the structure increasing the NC and cross-
linkage of silicon atoms, and in the case of BGs, this also leads to decreased bioactivity8,9,11. The glass 
transition temperature (Tg), in which the vitrification happens, is usually 100-400 °C below the Tc. 
However, the glasses are usually heated up to the liquidus temperature (Tl), in which the glass is 
completely liquified, because at the Tl and more, a more homogenous glass composition is acquired due 
to better diffusion of the ingredients. In melt-cast glasses, the crystallization is often avoided by rapid 
cooling or heating of the glass well past the Tc so there is not enough time for crystallization to occur.  
However, more advanced techniques have to be utilized to achieve more complicated and porous forms 
of the BG. The difference between the Tg and the Tc is often referred as the working range (ΔT = Tg - Tc), 
and the wider this is the easier glass processing techniques can be applied without the glass crystallizing. 
For example, sintering and fiber pulling require certain viscosity parameters to be effective, and if the 
glass starts to form small crystals or harden at various locations, the processing becomes hard or 
impossible. Consequently, a wide working range is a necessity.  
The crystallization tendency is directly related to the NC of the glass. Meaning that glasses with more 
open structure with less interconnectivity will crystallise earlier when heated than glasses with more 
cross-linked and dense structure8,9,46,50. Therefore, the working range can be altered by changing the 
structural network either by affecting the network connectivity or by changing the MO composition1,53–
56. By increasing the NC, the looseness in the structure and the molecular tensions in the structure are 
decreased which makes it less prone to crystallisation. Addition of silicon has been proven to widen the 
working range of the glasses4,8,54. The other ways that have been found to increase the working range 
and viscosity were to increase the alkaline earth/alkali metal ratio by removal of  alkali metals and 
increase in alkaline earth metals. High alkali content glasses have been recognised to have higher 
viscosity compared to glasses with higher alkaline earth to alkali metal ratio which raises the Tg and 
decreases processability54.  
Brink and others demonstrated that by utilizing the mixed alkali effect the working range can be further 
expanded54–56. By substituting Na2O with K2O or Li2O, the different ionic radii and ionic weight of the 
substitutions change the structural density of the matrix while retaining the change balance and 
network connectivity54,55. According to Tylkowski and Brauer55, the mixed alkali effect causes a decrease 
in the structural density, thus affecting the processability. Lithium has smaller ionic weight than sodium, 
but regardless of its also smaller ionic radius, it causes a net decrease in the density. Similarly but 
oppositely, potassium has a higher ionic weight than sodium, but its bigger ionic radius expands the 
structure and causes a net decrease in the density. Even though lithium and potassium have vastly 
different sizes and weights, they both have a similar effect on the thermal and physical properties of the 
glass causing a decrease in the Tg and increase in the Tc significantly improving the processability54–56.  
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Similar substitutions to the alkaline earth metal oxides causes comparable effects. Substituting CaO with 
MgO, the structural density decreases because of larger ionic radii of magnesium, and therefore 
improves the processability of the result glass57. However, magnesium can to a degree incorporate to 
the silicon structure and from BO bonds as a tetrahedra and consequently increase the NC at those 
sites57. According to the Watts et al., approximately 14% of the added magnesium usually acts as a 
network former regardless of the added amount57. Similar reaction can also be predicted with zinc as it 
has almost the same ionic radius as magnesium. Strontium substitution did not improve the processing 
window although it decreased the Tg it happened simultaneously with a decrease in the Tc58,59. 
Aluminium and titanium oxides can also be effective at widening the working range if kept at low 
contents so that the bioactivity remains largely unaffected51,53,54,60. 
Another factor to consider is type of crystals the used glass tends to form. There are multiple types of 
crystals that can form from the materials in BGs but usually only two of them are relevant – sodium-
calcium-silicate (NCS) and calcium-silicate (wollastonite)10,46,50. According to Arstila et al., generally the 
bioactive glasses crystallise to either type of these and it can be considered as an indication of the 
working range of the glass. Glasses that tend to crystallise into NCS typically have their Tg at around 
550 °C and Tc at 600-750 °C, while those glasses that tend to crystallise into wollastonite have their Tg 
at around 600 °C and Tc at around 850- 930 °C indicating a much larger working range for the latter10,46,47.  
However, it is important to remember that as the amount of silicon and interconnectivity is raising, also 
the bioactivity and rate of dissolution are decreasing. Therefore, it is always going to be a compromise 
between optimal bioactivity and processability, and the balance has to be found depending on the 
intended use or the desirable processing method.   
 
1.5 The Bioactive Glass Fibers, FRCs and Embroidery Technique 
Once the suitable working range has been found, bioactive glass can be processed without it losing its 
bioactivity. The processability allows the glass to be e.g. sintered at high temperatures to achieve porous 
scaffolds, processed into microspheres, or pulled into fibers56,60,61. The glass fibers are an attractive form 
of bioactive glass since from fibers it is possible to produce porous scaffolds; woven fabrics, strips, or 
threads; or implants with elastic properties. For example, fibers of bioactive glasses have been 
effectively used in neuroregeneration62, for weaving cloths which were wrapped around a defect to 
improve bone regeneration and wound healing63, to stimulate full-size skin wound healing64, and 
theoretically, they could be used to produce hollow BG fibers that could be used as a drug delivery 
vector65. 
Glass fibers can be combined together with a polymer matrix to create fiber reinforced composites (FRC). 
For example, in dentistry FRCs have been in development from 1960s and used in the clinics today16,66. 
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By reinforcing the polymer matrix with and glass fibers, it is possible to achieve new materials which 
are far more durable than the original materials and which can withstand more stress and torque. 
Additionally, the mechanical properties of the FRCs can be accurately engineered to the be more suitable 
for the various needs of a medical implant by changing the ratio of polymer to glass fibers or by using 
different polymer and glass compositions.  
The current implant materials used for fixation in bone reconstruction processes are mostly bioinert 
and biostable. Meaning that they will either stay in the body or require a secondary surgery to be 
removed after their initial purpose has been fulfilled. Additionally, an issue can arise if the implant 
material is too stiff. The bone might be exposed to stress shielding, a phenomenon commonly associated 
with metallic implants such as titanium16. During stress shielding,  the rigid implant takes the load off of 
the bone and the body recognizes the bone mass around the implant as unnecessary and starts to recycle 
it for reuse elsewhere. This causes recurring fractures, implant detachment, inflammation and 
ultimately surgical removal and a new reconstruction operation.  
It is beneficial to search for better alternatives to the metallic implants. The ideal option would be fully 
degradable implants but currently no such material is in commercial use. However, promising 
approaches that are in the right direction have been developed. Skull implants produced by Skulle 
Implants Oy (Turku, Finland) utilize porous composite casing made of inert fiberglass embedded into a 
polymer matrix and S53P4 bioactive glass laminated between the composite layers17,66–68. This solution 
is osteoinductive, allows bone ingrowth into the material and complete integration while mimicking the 
physical properties of a natural bone. While this kind of inert casing is required for large defects that 
would not heal by themselves, the permanent material leaves the area of injury prone to infections and 
inflammation67, suggesting that better alternatives could be pursued for smaller scale bone 
reconstructions. Fiber reinforced composites have been successfully used with bioactive glasses16,17,60,66. 
However, few have been able to successfully combine bioactive glass fibers with a polymer matrix60. It 
would be beneficial, if bioactive glass fibers could be bound into the composite itself because that would 
open up more possibilities for utilizing bioactive glass.  
Another promising application could be the medical embroidery techniques. They have been 
successfully used in tissue engineering applications using e.g. synthetic polymer threads and collagen 
fibers52,69–71. The embroidery techniques used in scaffold production are most often CNC assisted, 
automated processes in which the machine is programmed to weave the fibers into the desired shape69. 
Embroidery provides an interesting option for the production of solid but still porous scaffolds if strong 
enough BG fibers could be created and used as the source material. This would allow for fully 
computerized and automated prototype modelling that would make mechanical testing and sample 




1.6 The Bioactivity Profile of Bioactive Glasses 
In this study, three different types of bioactive glasses were used – 1-06, 13-93, and 18-06. These glasses 
have been developed at the Åbo Akademi University in Turku. They represent fast, medium and slow 
bioactivity profiles, respectively, according to the system created by Vedel et al47. They developed a 
computerized method for optimizing bioactive glass properties which can he used to create novel 
bioactive glasses with desired properties. The three different glasses that were chosen for this study 
represent wide working range with but differing bioactivity profiles and compositions.  
In Vedel’s study, the assessment of the bioactivity profile was calculated based on the changes in pH, 
phosphate concentration, and the thickness of the calcium phosphate layer during a 72h immersion in 
simulated body fluid (SBF)47. The change is pH was used to assess the speed at which the ions were 
releasing from the glass matrix, the change on phosphate concentration was used to assess the reaction 
rate, and the development speed of the calcium phosphate layer was used to determine a bioactivity 
number for the glasses.  
The knowledge of the bioactivity profile can be useful for predicting the behaviour and usability of the 
BGs in vivo. Since the glass processing techniques may affect the properties of the glasses, it is necessary 
to assess the bioactivity profile also for processed glasses.  
The purpose of this study is to produce fibers from 1-06, 13-93, and 18-06 bioactive glasses and assess 
their bioactivity profiles and their usability for load bearing implants. The ultimate goal is to find the 
most feasible composite material that could be used to create load-bearing implant that would support 
bone ingrowth and help with bone healing but also dissolve after its purpose has been fulfilled. 
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2. Materials and Methods 
 
2.1 Materials and the Experimental Design 
The BG 1-06 represents the fast bioactivity profile in this study. It has the lowest silicon composition, 50 
wt%, of the experimental glasses but also the highest calcium composition of 22 wt%. Therefore, it 
should the fastest dissolving and the most responsive to aqueous environment due to its low amount of 
Q3 -species in the structure, but also the high Ca/Na-ratio increases the bioactivity. 1-06 bioactive glass 
is expected to form a thick layer of calcium phosphate (CaP) during the study period.  
The BG 13-93 is a relatively old type of bioactive glass that was developed in 1993, and it is well known 
for its bioactivity and large working range11,47,54,61. Vedel et al. also considered it as a control in their 
study47. According to also Vedel et al.’s computerized method, 13-93 BG has medium bioactivity and 
wide working range. 13-93 has 53 wt% silicon and little lower Ca/Na ratio than 1-06. The 13-93 fibers 
are expected start showing signs of CaP-layer formation during the study period but still maintain their 
integrity.  
The BG 18-06 BG represents the slowest bioactivity profile and has the highest silicon composition of 
the experimental glasses at 65 wt%. 18-06 also has a really small Ca/Na ratio indicating a slow response 
to the aqueous solutions, but according to Vedel’s calculations, 18-06 should still be bioactive and 
resorbable. The 18-06 BG fibers are not expected to have any signs of CaP formation but possibly start 
to show signs of dissolution during the study period.  
For the evaluation of the bioactivity profile, 168 hour immersion in SBF is utilized with the sample 
collection points at 4, 8, 12, 24, 72, and 168 hours. In contrast to the Vedel’s method, pH measurements 
were omitted and replaced with the direct measurement of the ion concentrations of sodium, silicon, 
and calcium. The phosphate concentration was measured and used to assess the reactivity rate. The 
thickness of the CaP-layer was measured with a scanning electron microscope. 13-93 blocks were used 
as the positive control and the benchmark for the bioactivity profile according to the Vedel et al.’s study47. 
Inert E-glass was used as the negative control.  
 
2.2 Melting of the Bioactive Glasses 
The bioactive glasses were made in collaboration with Åbo Akademi University. The compositions are 
summarized in Table 1. The BGs were manufactured using the traditional melting method using a 
laboratory furnace and a platinum crucible. The same method has been utilized for BG production in 
multiple studies10,50,54,72–74 The ingredients were laboratory grade Na2CO3, K2CO3, MgO, CaCO3, CaHPO4, 
B2O and SiO2 (Thermo Fischer Scientific Oy, Finland, Vantaa).  The ingredients were weighed according 
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to the Table 1 separately for each type of glass, mixed thoroughly, and melted at the furnace at 1360°C 
for 3 hours. After the 3 hours, the melt glass was casted in a monolith-shaped ceramic mould and set to 
cool slowly in a secondary oven at 520°C to prevent it from shattering due to rapid shrinking after 
thermal expansion. The power was cut from the secondary oven after 2 hours and glass plate was 
collected the next morning.  
To achieve homogeneity, each BG plate were shattered after they had set at room temperature and the 
shards were re-melted and cooled using the same protocol as in the first melting.  
Table 1. Compositions of the used bioactive glasses. Ingredients as wt%. 
 1-06 13-93 18-06 E-glass 
SiO2 50.0 53.0 65.0 53.0 
Na2O 5.9 6.0 18.4 <1 
CaO 22.6 20.0 15.0 11.0 
P2O5 4.0 4.0 - - 
K2O 12.0 12.0 - <1 
MgO 5.3 5.0 0.1 11.0 
B2O3 0.2 - 1.5 10.0 
Al2O3 - - - 14.0 
 
 
2.3 Pulling of the Glass Fibers 
For the fiber pulling, the produced glass monoliths were shattered and re-melted again at the platinum 
crucible at the 1360 °C. The fibers were pulled manually from the crucible using a ceramic rod. There 
was no method for monitoring the temperature of the glass melt, so after we removed the glass melt 
from the furnace, the viscosity of the glass was tested with the ceramic rod and the pulling was started 
when the melt had congealed enough that the viscosity allowed pulling of the glass without the fiber 
breaking. Because of the multiple cooling and re-heating cycles, we determined a maximum of four re-
heatings per glass melt was allowed before the crystallisation of the glass started to disturb the pulling 
process and the quality of the glass.   
2.4 Dissolution Test 
2.4.1 Preparation of the Samples 
A novel method was created for preparing the samples for the dissolution test. Fusion deposition 
modelling (FDM) technique was used to create a scaffold that would fix the fibers in place so that they 
would be consistent and easier to handle during the tests. The scaffold composed of a series of 4x4 mm 
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(2,9x2,9 mm inner diameter) rectangles that were connected with a spine that linked the rectangles 
together (Figure 1). The scaffold was produced from commercial PLA (Clas Ohlson) and the 3D-printer 
used was a MiniFactory 3D-printer (miniFactory Oy LTD, Seinäjoki, Finland).  
First, four layers were printed on the print-surface glass. Since the PLA sticks strongly to the glass, a thin 
layer of general adhesive (Erikeeper, Oy Sika Finland AB, Espoo, Finland) was used to coat the surface 
glass substrate to facilitate removal of the printed scaffold without damaging it. After the fourth layer, 
the printing was paused and a bundle of glass fibers (~15 fibers) was placed on the scaffold. The fibers 
were fixed to the enlarged wings at both ends of the scaffold with double-sided tape (3M). Afterwards, 
the print was finished by printing three layers of PLA on top of the fibers which fixed the fibers to the 
scaffold. 
                  
Figure 1. Concept picture of the 3D-printed scaffold.  
 
The fiber bundles were prepared manually by picking and cutting fibers of roughly equal thickness. The 
fiber bundles were fixed in place with double sided tape (3M) from both ends on a thin clear film. The 
film was cut out under the fibers leaving the film only to the ends. The thicknesses of the fibers were 
0.12 mm for 1-06 and 18-06 and 0.07 mm for 13-93. Thickness of the E-glass fibers used as a negative 
control was 0.01 mm and the 13-93 used as a positive control were 1.0 mm.  
 
2.4.2 Ion Release  
For the ion release test, simulated body fluid (SBF) was prepared according to the Kokubo and 
Takadama’s method75, and the printed scaffold was cut into singular rectangular glass fiber samples. 
The correct SBF amount was calculated according to the Equation 1 which was taken from the Kokubo 
and Takadama’s article. The calculated amounts per one square was 16.4 ml for 1-06 and 18-06, 12.3 ml 
for 13-93, 10,0 ml for E-glass and 1,0 ml for 13-93 blocks. For the 1-06 and 18-06, two squares were 
used and the used amount of SBF per specimen was 32.8 ml, and for the 13-93, three squares were used 
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in 36.9 ml SBF. For 13-93 blocks, 10 blocks were used to increase the amount of SBF to 10,0 ml so that 
it has some buffer to take samples. For the E-glass, one square was used in 10,0 ml SBF. Three replicates 
were used for the bioactive glass specimens, two replicates for the E-glass and one for 13-93 blocks.  
Equation 1. Volume of the SBF needed for the tests. x= number of fibers, r= radius of a fiber, [r]=mm, l=length of 











The calculated amounts of SBF were pipetted to factory sterilized 15 ml Falcon tubes (VWR 
International Oy, Helsinki, Finland) with sterile pipet ends. The other used instruments and the 
specimens were immersed in 70% EtOH for 5 minutes prior and air dried in fume hood until dry. The 
specimens were immersed in SBF and the tubes were places in a water bath shaker at 37 °C. A 1.0 ml 
sample was taken from each tube at 4, 8, 24, 72, and 168-hour time points. The samples were placed 
into 1.5 ml Eppendorf tubes that were first sterilized in 70% EtOH. The samples were stored in a 
refrigerator at 5 °C until the analyses began.  
The SBF samples were analysed with inductively coupled plasma optical emission spectroscopy (ICP-
OES) at Åbo Akademi University. For the ion release analysis, the samples needed to be diluted in 1:9 
ratio, so 0.9 ml of the SBF sample was taken and diluted to 8.1 ml of purified water in a clean 15 ml 
Falcon tubes (VWR International Oy, Helsinki, Finland).  
 
2.5 Scanning Electron Microscopy (SEM) 
After the immersion 168-hour immersion in SBF, the specimens were rinsed with purified water, 
transferred to a well plate, and placed to dry in a heat chamber at 37 °C. The samples were prepared for 
SEM after 48 hours. From each group, one sample was prepared for cross-sectional images and the 
remaining two for surface images.  
The cross-sectional samples needed to be embedded into resin to achieve a clean cut from which the 
thickness of the calcium phosphate layer could be measured. For the embedding, a rectangular-shaped 
mould was created from Lab Putty silicone and hardener (Coltène/Whaledent AG, Altstätten, 
Switzerland) using a rectangular wooden spacer. After the mould had hardened for 48 hours, immersed 
specimen was fixed into the mould using a staple to keep it from moving during the pouring of the resin. 
20 g of resin and 8 g of hardener (RSF 816, Axson Technologies, Baar, Switzerland) was mixed in a 
vacuum mixer (THINKY – Planetary Vacuum Mixer: 1000 rpm, 4.5 mb, 5 min) to remove excess air 
bubbles. After pouring the resin into the moulds, the moulds were placed into vacuum oven (Memmert) 
for 1 hour (10 mb, 25 °C) and during this time, the pressure was briefly reset to normal every 15 minutes 
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to reduce the size of bubbles that formed and prevent overflowing. After the first hour, the temperature 
was increased to 60 °C and the pressure was returned to normal air pressure for 2 hours to hasten the 
polymerization process. The resin was then left to polymerize for 96 hours in RT.  
The fully polymerized resin was cut with a histological saw (2200 rpm, 0,5mm/s) in the middle of an 
immersed sample so that the cross section of the fibers could be revealed. After cutting, the cross-
sectional part was polished with a sanding device with #1000 and #4000 roughness sandpaper while 
using EtOH as the lubricative liquid until the surface was clean and reflective. All of the samples were 
then coated with carbon to achieve a conductive surface for the SEM. The coating was done in high-
vacuum chamber and with a carbon thread while the specimens were fixed on a small stand.  
Representative images of the surface and cross-sectional samples were taken with SEM. The images for 
the surface images were taken with the smallest magnification (x220-245) and x700 magnification, and 
for the cross-sectional images, the smallest and x900 magnification was used. The thickness of the 
calcium phosphate layer was measured manually from the taken images and transformed to the actual 
scale.  
 
2.6 Energy-Dispersive X-ray Spectroscopy 
An Energy-dispersive X-ray Spectroscopy (EDS) was conducted simultaneously with the SEM to 
determine the elemental compositions of the immersed fibers and to confirm the formation of CaP. 
Images were taken from five to six fibers from all experimental glass types, and the spectroscopy was 
performed in the middle and the edge parts of each fiber and additionally on all other visible layers if 





3.1 Ion Release Analysis 
Ion release analysis was done with ICP-OES, and the results are shown in Figures 2-5. The analysis was 
done to silicon, sodium, phosphorus, and calcium ions over 4, 8, 24, 72, and 168 hours.  
The baseline for silicon in SBF is 0 mg/l and the changes in SBF silicon concentration are in figure 2. A 
steady exponential decrease in the release of silicon can be seen from 13-93 blocks. The release curve 
of 13-93 block has a steep initial slope to 5.1 mg/l in the first 24 hours which then gradually declines to 
a flatter curve while still slightly increasing at 6.5 mg/l at 168 hours. 1-06 releases silicon at near 
constant rate to 1.6 mg/l at 72 hours and is still increasing at 2.5 mg/l after 168 hours. 13-93, 18-06 and 
E-glass do not release silicon ions even after 168 hours of immersion and present a flat curve at 0.0 mg/l 
until the end of study period. 
 
 
Figure 2. Si-ion concentration of 1-06, 13-93, 18-06, and E-glass fibers and 13-93 bioactive glass blocks in SBF over 
time.  
 
The measured baseline for the phosphorus concentration in SBF is 3.6 mg/l, and the changes in the SBF 
phosphorus concentration can be seen in the Figure 3. The changes in the phosphorus concentration are 
due to the phosphorus being bind into the calcium phosphate layer that is forming on the surface of the 
bioactive glasses. The 13-93 blocks decrease the phosphorus concentration at a steady rate of 23 µg/l/h 
and reach 0.0 mg/l in 168 hours. Also, the 1-06 fibers decrease the phosphorus content at a steady rate, 
approximately 12 µg/l/h, and reach 1.8 mg/l in 168 hours. The 18-06, 13-93 and E-glass fibers maintain 































Figure 3. P-ion concentration of 1-06, 13-93, 18-06, and E-glass fibers and 13-93 bioactive glass blocks in SBF over 
time. 
 
The measured baseline calcium ion concentration in SBF is 10.2 mg/l and the changes of the calcium 
concentrations are showed in the Figure 4. The SBF and the bioactive glasses contain calcium so both 
can contribute to the measured calcium concentration. 13-93 blocks present a quick initial release of 
calcium until 24 h to 15.2 mg/l, followed by a small decrease in concentration at 15.0 mg/l at 72 h, and 
continuing increasing up to 16.8 mg/l by the 168 h. 1-06 fibers increase the calcium concentration up 
to 11.0 mg/l for 24 h which then starts to decrease at a near constant rate below the baseline down to 
8.8 mg/l by the end of the test period. 13-93, 18-06, and E-glass fibers again present a similar curve to 
each other; a small initial increase during the first 8 h up to 10.4 mg/l and then staying constant close to 
the baseline for the rest of the test period.  
 
 





























































The measured baseline for the potassium concentration is 20.8 mg/l, and the changes in the potassium 
concentration in the SBF can be seen in the Figure 5. The 13-93 blocks had a rapid increase in the 
potassium concentration to 26.1 mg/l over the first 24 h and gradually smoothening the increase and 
reaching 32.7 mg/l at 168 h. 1-06 had a faster initial increase reaching 21.6 mg/l over the first 24 h and 
then at a slightly slower rate increased to 22.6 mg/l over the rest of the test period. 13-93, 18-06, and 
E-glass fibers had a similar curve though out the study period. They presented an initial increase to 21 
mg/l during the first 8 hours until reverting back to baseline level at 24 h for the rest of the test period.  
 
 
Figure 5. K-ion concentration of 1-06, 13-93, 18-06, and E-glass fibers and 13-93 bioactive glass blocks in SBF over 
time.  
 
3.2 SEM Analysis  
The SEM analysis of the immersed bioactive glass fiber samples reveals the formation of surficial 
calcium phosphate layer. The surface images are presented in the Figure 6 and the cross-sectional 
images are in the Figure 7.  
In the Figures 6A, 6B, 7A, 7B, a thick layer of calcium phosphate has formed on the surface of the 1-06 
fibers. Calcium phosphate covers the whole surface area of the fibers, and the layer is approximately 
16.6 µm (SD = 4.6 µm, n = 20) thick. The calcium phosphate layer has cracked in multiple positions, 
possibly due to shrinking during the drying process. The calcium phosphate layer also has multiple 
differently sized granules on its surface. From the cross-sectional images (Figures 7A, 7B), definite four-
phase layering can be observed – an intact untransformed glass in the middle, a darker silicon-rich 
section above the middle, a transition layer between the Si-rich area and the calcium-phosphate layer 
above that, and the calcium-phosphate layer on the surface of the fibers.  
In the figures representing 13-93 (Figures 6C, 6D, 7C, 7D), a definite layer cannot be seen on any of the 






























multiple tiny granules all around their surface (Figure 6D). The cross-section images also prove that no 
definite layer formation has occurred (Figures 7C, 7D). The edges of the fibers are fractured possibly 
due to sanding during the sample preparation.  
In figures representing 18-06 ( Figures 6E, 6F, 7E, 7F), no definite layer can be seen, and the intact 
surface is completely clear of deformations on all of the fibers. In the fibers that had grooves, some tiny 
granules had formed inside the groove. The cross-sectional images (Figures 7E, 7F) also contain no 
evidence of layer formation. The edges are damaged also on 18-06 fibers possibly due to sanding during 
the preparation.  
In the figures 6G, 6H, 7G and 7H that represent E-glass, no layer formation or surface alteration can be 
seen on any fiber. The surface is clear in the great majority of fibers. Some unidentified crystals could be 
seen on separate locations (images not shown), however elemental analysis was not conducted to find 
out their composition. Similarly, the cross-sectional images present no evidence of layer formation. 
Additionally, multiple damaged fibers can be seen in the cross-sectional images.  
 
3.3 Energy-Dispersive X-ray Spectroscopy 
The data from EDS was translated to show the true SiO2, Na2O, and CaO composition of the immersed 
fibers. The results are shown in Table 2. The 1-06 fibers had 52.4 wt% SiO2, 6.0 wt% Na2O and 21.3 wt% 
CaO. The 13-93 fibers had 70.6 wt% SiO2, 13.7 wt% Na2O, and 14.4 wt% CaO. The 18-06 fibers had 71.7 
wt% SiO2, 15.8 wt% Na2O, and 14.7 wt% CaO. The 1-06 had 2.4 %-unit more silicon and 1.3 %-unit less 
calcium than the intended glass composition (Tables 1 and 2). The other measured compositions fail to 
represent the intended  compositions. The 18-06 fibers had 6.7 %-unit more silicon and 2.4 %-unit less 
sodium, and the 13.93 fibers had 18,6 %-units more silicon, 7.7 %-unit more sodium, and 5,6 % unit less 
calcium than intended (Tables 1 and 2). 
 
Table 2. The true composition of the 1-06, 13-93, and 18-06 BG fibers according to the EDS results. Showing the 
wt% of the SiO2, Na2O, and CaO contents.  
1-06 13-93 18-06 
SiO2 52.4 70.6 71.7 
Na2O 6.0 13.7 15.8 





Figure 6. Surface SEM images of the 1-06 (A, B), 13-93 (C, D), 18-06 (E, F) and E-glass (G, H) at 220-230x 




Figure 7. Cross-section SEM images of the 1-06 (A, B), 13-93 (C, D), 18-06 (E, F) and E-glass (G, H) fibers 





4.1 Assessment of the Bioactivity Profile and Evaluation of the Results 
The purpose of this study was to determine the bioactivity profile for the 1-06, 13-93, and 18-06 
bioactive glass fibers and discuss if they are suitable for use as structural parts  of a novel biodegradable 
load-bearing implant.  
In study by Vedel et al.47, 13-93 was assessed as medium degree of reactivity with a rapid dissolution of 
ions, medium reactivity rate (3.2 out of 5, the higher the more reactive) and medium bioactivity number 
(2.3 out of 3, the higher the more reactive). Establishing this as the control bioactivity profile for a 
medium BG, establishing the E-glass profile as a control for no bioactivity, and using the data from 13-
93 blocks and E-glass fibers, a rough evaluation of the bioactivity profile for the BG fibers can be 
estimated.  
1-06 BG fibers released silicon, sodium, and calcium more slowly than the 13-93 blocks (Figures 2, 4, 5) 
and the reactivity rate was slower than 13-93 blocks (Figure 3). However, the calcium phosphate layer 
thickness was not measured from the 13-93 blocks making it challenging to address the relative 
thickness of the CaP-layer on the 1-06 fibers. Regardless, this would probably place the 1-06 fibers on 
the lower end of the medium bioactivity profile. 13-93 and 18-06 fibers had similar ion release, 
reactivity rate and CaP-layer formation behaviour throughout the test, and they followed the same 
pattern as the negative control (Figures 2-7). Since there was relatively no release of ions, no reactivity 
from the baseline and no CaP-layer formation, both 13-93 and 18-06 fibers represent nonreactive or 
really slow bioactivity profile. The bioactive glasses were supposed to represent fast, medium, and slow 
bioactivity profiles; however, the study results suggested the bioactivity profile was medium for 1-06 
fibers and nonreactive for 13-93 and 18-06 fibers.  
After immersion to the SBF, the dissolution of the 1-06 fibers can be observed in Figures 2, 4, and 5. 
Consequently, the formation of the calcium phosphate layer can be observed from the SEM images in 
the Figures 3, 6, and 7. Also, the decline in phosphate concentration in the SBF analyses indicates that 
the calcium phosphate is crystallising. However, 13-93 and 18-06 bioactive glass fibers react similarly 
to the negative control fibers in the dissolution test and SEM analysis and did not display signs of 
bioactive behaviour. This could mean that the test period was not long enough for the dissolution to be 
observable and they could both represent the slow bioactivity profile. However, judging by the rapid 
dissolution of the 13-93 blocks, it is unlikely to be the case indicating that the fiber pulling process 
affected the glass structure or composition.  
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The EDS analysis revealed the composition of the immersed fibers and confirmed that the compositions 
were altered for all of the fibers (Table 2). 1-06 and 18-06 BG fibers have more silicon than intended but 
the amount of sodium and calcium are within 2%-unit in both glasses (Tables 1 and 2). 13-93 fibers 
have roughly 6%-unit difference in MO content having more sodium and less calcium than intended 
(Tables 1 and 2). However, the increase in the silicon content by 18.6 %-unit in the 13-93 fibers and by 
6.7 %-unit increase in the 18-06 fibers which already had  a high silicon content probably caused them 
to lose their bioactivity by increasing the NC too much. This probably explains the lack of calcium 
phosphate layer formation during the SBF immersion for both glasses. According to Hench’s early 
studies1 the bioactivity starts to decrease fast after the silicon contents pass the 60 wt% point. 
Additionally, Brink et al. tested a variety of bioactive glasses to find out the limits for the BG composition, 
and they came up with the same approximately 60 wt% upper limit for the silicon content. 
In regard of using these fibers in an implant design, the 1-06 fibers could probably be used on the 
surfaces of the implant to act as a highly active interface between the implant and the bone. Since these 
fibers were 41% transformed into calcium phosphate during the study period, they would dissolve 
quickly and facilitate better attachment of the implant to the host tissue. Presuming an exponentially 
decreasing transformation rate, it would take up to around one to one and a half months for the 1-06 
fibers to transform completely. This could still be too fast to consider the 1-06 fibers as the main 
structural component of a load-bearing implant.  
The results of this study cannot conclude the speed of degradation or the bioactivity of the 13-93 or the 
18-06 fibers, and therefore additional and probably longer studies with the slower types of bioactive 
glasses would have to be conducted. Also, the mechanical integrity and strength would have to be 
assessed to determine the usability of these fibers for load bearing applications.  
 
4.2 Fiber Pulling Methodology  
The manual fiber pulling process is probably not an ideal method for achieving consistent fiber quality. 
In this study, the fibers came out in varying thicknesses and the composition had changed significantly 
from the intended structure. Since the fibers were pulled from the top of the glass melt, it is possible 
that the fibers only represent the most surficial layer of the melt glass and therefore fail to represent the 
holistic consistency of the glass due to the glass being phase separated or improperly homogenized3,9,55. 
Furthermore, the surface of the glass melt is also the most susceptible for crystallization76 and 
incorporation of impurities or flaws to the fiber structure more easily. The pulled fibers are also very 
thin, which requires an even distribution of the ions is the glass structure so that the fibers would have 
the sought composition. However, researchers have been successful in pulling for example 13-93 fibers 
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with the intended composition using similar manual methods61,72 implying that there could be an 
execution error in the present study.  
Bioactive glass fibers have been pulled using a spinner since 1990s77 by pulling the fibers from an orifice 
on the bottom of the furnace. Marcolongo et al.77 achieved good quality fibers by this method using a 
fixed temperature during the pulling. Pirhonen et al.76 used a same method for melting and remelting 
the glass as in this study but they also used a spinner a to collect the fibers on a reel. With a reel, it is 
possible to pull with a constant speed and collect consistent fibers that have even thicknesses. 
Furthermore, by with this method it is possible to keep the crucible in the furnace and have the melt 
glass at a fixed temperature from which the fibers are pulled. By doing this in the present study, the 
quality of the glass fibers would have probably been improved since by taking the crucible out of the 
furnace, the glass starts to cool immediately, and it becomes challenging to control the temperature. In 
the present study, the viscosity of the glass was tested manually and the fibers were pulled with a rod 
instead of letting then flow through an orifice definitely created more variability to the pulling process.  
Interestingly, Brink et al. used a different fiber manufacturing method in another study78. They had the 
similar glass production and melting system used in the melt-spinning technique, however instead of a 
spinner, they used a spinning stainless steel plate on which they poured the melt glass. The diameter of 
the fibers was controlled by altering the speed at which the plate was spinning. Although they did not 
mention the exact diameter of the produced fibers, the figures on the article showed really fine gauge 
fibers definitely in the sub 100 µm scale, probably around few tens of µm in thickness.  
Lately, more advanced fiber pulling methods have been created. Researchers have been able to produce 
fibers from bioactive glasses using a technique called electrospinning79,80. This technique is widely 
utilized in the BG fiber research mainly because it allows the creation of nanoscale fibers and porous BG 
scaffolds79–81. Deliormanli81,82 was also able to create fibers from the 13-93 using this method. 
Electrospinning is a technique that utilizes sol-gel type BG and an electrical field. The glass solution is 
slowly released from a syringe into an electrical field which then pulls the liquid towards a spinning reel. 
The thin stream of BG solution quickly polymerizes in the air into nanoscale fibers which can be then 
collected from the reel for further processing. This technique however is not feasible for the production 
of fibers with larger thicknesses since the liquid stream needs to be light enough to travel in air while 
being pulled by the electrical field.  
Another technique called laser spinning was first introduced in 2009 by Quintero et al83. Laser spinning 
utilizes a high energy laser to melt the end of a solid glass block and then using a high-powered gas flow 
which blows and elongates the melting droplet effectively pulling it into a fiber. As the melting and 
blowing happens nearly instantaneously, this allows for really rapid fiber pulling. In their study, they 
demonstrated this technique by pulling 45S5 and 52S4.6 bioactive glasses into fibers and immersed 
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them in SBF to demonstrate the preservation of bioactivity. And a result, the glasses produced calcium 
phosphate layers in 5 days. They also used X-ray fluorescence and a magic angle spinning NMR to verify  
the composition of the fibers, and even thought composition was slightly altered, they had essentially 
the intended composition. 45S5 is notorious for having a narrow working range and so far researchers 
have been unable to pull it into fibers without it crystallizing10,11,46,47,50,74. According to the author, the 
nearly instantaneous melting and cooling cycle prevents the glass from crystallizing and preserves the 
amorphous state. Furthermore, the laser spinning technique yielded nanoscale fibers that remained 
separated on the reel while being flexible and easily arrangeable for further processing. This makes laser 
spinning a very feasible fiber pulling technique for especially for bioactive glasses because it allows 
fibers to be pulled from virtually any BG, also form narrow working range bioactive glasses, while 
keeping them easily workable.  
Learning from these previous studies, using a spinner to pull the fibers at a constant rate and at a fixed 
controllable temperature seems to be the best method for pulling good quality fibers in non-industrial 
setting when not in need of nanoscale fibers and unable to acquire complex equipment. Also, adding 
multiple remelt cycles to the process seem to be the best method for obtaining a more homogenized 
consistency for the bulk glass76,77.  
 
4.3 Estimation of Cell Toxicity  
In order to create a successful implant, the cell toxicology would also have to be assessed. According to 
the literature, 13-93 BG fibers are compatible with osteoblasts and are not cytotoxic82. 13-93-based 
products are also approved for in vivo use in the Europe84. Cell cultures with 1-06 BG stay viable and 
induce osteogenesis in adipose stem cells19,85,86. However, no studies using 1-06 BG fibers in cell cultures 
could be found. Similarly, studies using 18-06 BG in any form could not be found in a literature search 
from Web of Science or PubMed.  
In a comparable study, Valerio et al. used a high silicon content BG in their cell culturing studies while 
trying to assess the effects of bioactive materials on the differentiation, proliferation, viability of rat 
primary culture osteoblasts87. They used a 60 m-% SiO2 and 35 m-% CaO, and 5 m-% P2O5 BG that was 
produced with the sol-gel method. The high silicon content triggered a vacuole formation inside the cell 
membranes, but the cells remained viable, preserved their natural morphology, had increased 
proliferation and collagen production, and reached confluence in the culture plate. In the study, they 
demonstrated that the vacuole formation was because of the high silicon content and that the vacuoles 
contained 75% more silicon than other parts in the cells. Whether this causes toxicity or systemic issues 
in vivo remains unanswered, but this gives some evidence that bone cells react well to high silicon 
concentration from BGs.  
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In another study, Karpov et al.88 used an even higher silicon content BG glass while assessing the effects 
of sol-gel glass ceramics to the differentiation and viability of heterogenous mixture of human bone 
marrow cells, consisting of osteoblasts and osteoclasts among others. The other glass they used was an 
80 % SiO2, 16 % CaO, and 4 % P2O4 BG that was produced by the sol-gel method. In contrast so the study 
by Valerio et al., this glass greatly enhanced osteoblast differentiation in the culture which was 
demonstrated by marked increase in ALP mRNA accompanied with decreased expression of 
osteopontin which is a known to inhibit calcification89. In this study, no vacuole formation or other cell 
toxicity issues were reported. On the contrary, the bone cells responded better to the culturing 
environment in the presence of BG while the culture lacking BG favoured the growth of fibroblasts.  
The two aforementioned studies used different cell lines (rat and human) which may contribute to the 
difference in reaction to BG’s ionic dissolution products, and also the combination of different culture 
mediums cause variance in cell response. Overall, despite the high silicon content, BG does not seem to 
cause major adverse reactions in the cell cultures implying that they are mostly safe to use with bone 
cells. However, more detailed research has to be conducted before unambiguous claims can be made.  
 
4.4 Fiber Reinforced Composites 
A bioactive implant has to match the modular and flexural properties of natural bone to become 
successful as a therapeutic device. By themselves, the glass fibers are rigid but have poor elastic 
properties and load-bearing capabilities90. To increase the feasibility of the fibers, they can be combined 
with synthetic polymer matrices that can be cured into rigid polymers. Together the fibers and the 
polymer create a composite that can be engineered to match the structural properties of the cortical 
bone and becoming a more natural bone-like material than the traditional metallic options66.  
Fiber reinforced composites are traditionally made form inert glass fibers and coupling it with 
thermoplastic or thermoset polymer. Thermoplastic resins, such as polyethylene, polyetheretherketone, 
or polyacetal, are first melted and the fibers are added to the melt resin. The fibers become embedded 
to the polymer matrix as the resin polymerizes. This results in the fibers being physically attached to 
the polymer matrix as they become entrapped during the polymerization. Thermosets in biomaterial 
science are usually epoxy resins, such as bis-glycidyl-A-dimethacrylate and 
triethyleneglycoldimethacrylate copolymer. Epoxy resins achieve higher cross-linking of monomers 
than the thermoplastics and therefore become stiffer but simultaneously more brittle66. However, due 
to the monomer nature of the resin, the fibers can be sized with a silane coupling agent which will 
chemically bond the fibers to the polymer during the curing. Because of the free radical based 
polymerization, thermosets have to be cured to achieve more complete polymerization. The curing is 
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often induced with specific wavelength in the blue scale of light, and in addition to heat, the material can 
achieve close to perfect polymerization.  
The biocompatibility of the traditional FRCs is good. They are built relatively bioinert, so they cause 
minimal foreign body reactions in the host. The FRC implants are permanent, so the purpose of the FRC 
implants is to support the healing of injury and afterwards stay as unnoticeable as possible by mimicking 
the natural properties of the bone. With the thermosets, unpolymerized epoxy monomers are toxic and 
can cause inflammatory response if the unpolymerized fraction is too high91,92. However, when fully 
polymerized, they have acceptable biocompatibility and minimal cytotoxicity68.  
 
4.5 Biodegradable FRCs 
Biodegradable polymers, such as poly lactic acid (PLA), poly glycolic acid (PGA), or polycaprolactone 
(PCA), have been clinically used for decades as sutures, and they are generally regarded as 
biocompatible. And as an added benefit, they dissolve in the body naturally. However, because of their 
degradative nature, they lose their structural integrity and stiffness quickly in wet conditions93 making 
it challenging to design load-bearing implants that would support the injury until the regenerated bone 
can support the load. Additionally, the mentioned polymers consist of acidic monomers meaning that 
dissolution products are acidic and lower pH of the local environment, which can cause inflammation 
and lead to implant failure94.  
However, in practice, the combination of these biodegradable polymers and bioactive glasses would 
make an ideal composite material. It would be fully biodegradable, osteogenic, osteoconductive, and it 
would have self-neutralizing dissolution products that counteract the acidity of the polymer with the 
alkalinity of the BG. The remaining challenges are to design an implant that would be load bearing and 
also to have customizable degradation rate to help create the optimal healing environment.  
One of the first attempts at creating fully biodegradable implants with bioactive glass fibers are from 
the late 1990s, when Marcolongo et al. created bioactive glass fibers from their own composition (52 
m-% SiO2 and 15 m-% CaO, 30 m-% Na2O, 3 m-% P2O5) and combined it with biodegradable sulfone 
polymer77. The implants had sufficient bioactivity in in vitro environment but the polysulfone dissolved 
too quickly for load bearing applications. In their following study60, Marcolongo et al. demonstrated that 
this composite material formed adequate bone bonding in in vivo environment with only one failure out 
of 36 specimens and without marked fibrous capsule formation or inflammation in the animals. 
However, this study was designed to measure the bone bonding ability and biocompatibility and not the 
load bearing capabilities. They also recognised this in their discussion suggesting that the load bearing 
applications should be further investigated. Although, good bone bonding capability of biodegradable 
composite had already been established at this point.  
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In 2010, Alm et al. fabricated a composite by weaving a mesh of 1-98 BG and PLGA polymer in 80/20 
ratio of PLA to PGA95. They implanted the mesh in New Zealand white rabbits to hold an autologous 
bone graft. All implants bonded with bone with the BG fibers almost completely resorbed in 12 weeks. 
No reported inflammatory reactions. However, this composite was not evaluated as osteoproductive 
rather only osteoconductive. While it did promote bone formation and bonding compared to the intact 
unoperated bone, it was not significantly more than the PLGA mesh without BG. Also, the defects were 
not critical size so they would heal by themselves over time. In conclusion, biodegradable fully woven 
composite could probably work in some clinical applications such as fracture or graft supporting 
scaffold, it probably would not work in applications requiring load bearing capability due to the lack of 
hard structural elements.  
More recently, Kharazi et al. produced a partially biodegradable composite bone plate from poly L-lactic 
acid (PLLA) and 13-93 fibers96, and it was intended to be used for fracture fixation. The composite was 
built by compressing two PLLA fiber sheets around silane sized BG fiber sheet with a hot press acquiring 
a chemical bond between the components and fully polymerized PLLA layers. In the animal tests, bone 
plates were placed in New Zealand white rabbits and half of the samples were bonded at the 4 week test 
group (n =15) and 73% were bonded at the 8-week test group (n=15). Moderate inflammation was 
observed in both groups, however the inflammation score decreased markedly from 0.8 at 4 weeks to 
0.33 at 8 weeks at a scale of 0 to 4 with 0 meaning no inflammation and 4 meaning severe inflammation. 
The positive biological response implies that this composite retains its bioactivity, and the inflammatory 
and fibrous capsule formation are mostly very mild or non-existent. They also tested the rate of 
degradation which remained constant throughout the testing period. No sign of exponential degradation 
was present. According to the study title, the implant was intended to be load bearing, however, the 
study was lacking the mechanical tests to demonstrate the load bearing capability. They claimed that 
the load was supposed to transfer on new grown bone after one month of implantation, which very well 
might be true in the case of fracture fixation.  
In another recent study, Wu et al. tested a novel commercial BG/poly L-D-lactic acid (PLDLA) composite 
plates for their biocompatibility and bone regenerative capabilities97. The composite was sold by a 
Finnish Arctic Biomaterials Oy, however they did not disclose the composition of the used BG. On the 
company website, the composite appears to be a mixture of a thermoplastic polymer and glass fibers in 
a random alignment which has been extruded or injection moulded into shape98. They claim to be using 
some proprietary manufacturing techniques called Automated Fiber Placement which allows them to 
computerize the optimal fiber placement, and they claim to be the first company providing load bearing 
biodegradable composites for medical use. In the published study, Wu et al. had the composite re-
processed at a Chinese company into small pins that were inserted into bone and muscle tissues of 
Beagle dogs97. The pins had a fiber fraction of 27,5 % and longitudinal parallel fiber. In the two year 
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study, the composite demonstrated excellent biocompatibility, and bone bonding and osteoproductive 
capability.  The composite performed superiorly to the plain PLDLA polymer in regard of tissue contact, 
angiogenesis, and bone regeneration for the first year.  
In another study by the same research group, they assessed the mechanical and degradative properties 
of the same PLDLA/BG composite over the same period of time99. Also in this study, the composite 
material performed superiorly to the plain PLDLA in terms of strength retention and degradation rate 
for the first half of a year. The composite demonstrated superior mechanical characteristics for the first 
52 weeks and remained relatively stable for the first 26 weeks which according to the authors would be 
enough for most clinical load bearing applications. After 52 weeks, the composite started to degrade 
faster possibly due to number of interconnected pores left by the degraded BG fibers. All in all, this 
composite material is so far the most promising option for clinical load bearing applications, and these 
long term in vivo studies support the clinical relevance.  
 
4.6 Designing Biodegradable Implants 
The material choice is the first step in creating a biodegradable composite. Based on the studies 
presented in the previous chapters, mixture of both L and D isomers of poly lactic acid and poly glycolic 
acid seem to be the most utilized materials for the polymer. They offer great processing capabilities and 
a possibility to freely engineer the mechanical and degradative properties while being largely 
biocompatible. They retain their shape and mechanical strength for a long time making them feasible 
also for supporting the regeneration of large defects. For example, PLDLA (L/D ratio of 80/20) retains 
its shape for over 2 years and their mechanical strength relatively stable for over a year before it starts 
to degrade more rapidly at around one and a half to two years97,99.  
The choice for BG fibers is little more complicated, since the BG has to have large working range and be 
sufficiently bioactive, which have been proven to be at the opposite ends of the compositional range73. 
In regard of the fibers used in the present study, more studies have to conducted on 1-06 and 18-06 
fibers to find out their eligibility for implant construction. However, degradation and mechanical studies 
have been conducted on 13-93 fibers by other researchers. According to the study by Pirhonen et al., 
the 13-93 fibers steadily lose their structural integrity during the first 5 weeks, but maintain nearly 
constant mechanical strength afterwards for about 40 weeks72. They speculated that this phenomenon 
was because of the calcium phosphate layer reached a critical level of thickness at which it starts to slow 
down the further degradation of the fibers by inhibiting the water penetration. While this is an 
interesting discovery, this kind of change in the dissolution characteristics necessitates further studies 
regarding the changes in the long term degradation rate and physical properties based on the 
composition of the BG fibers both in vivo and in vitro. It would be helpful to find out the exact time points 
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for certain BG fibers where they reach the limits of load bearing capability and flexural strengths. It is 
also interesting to know if the starting point of the slower degradation could be controlled, and how 
much of the original strength can be maintained at this state.  
While there are studies that have discovered the compositional range for BG that is both workable and 
bioactive8,54,55,73, there is a lack of comprehensive studies addressing the compositional dependence of 
both components of composite fibers on their mechanical behaviour and bioactivity in aqueous 
conditions. Since the behaviour of the separate components can be vastly different on their own than 
when they are used together, the compositional dependence of the composite components is vital for 
implant design. For example, the acidic degradation products of the polymer can have a slowing effect 
on the degradation of the BG fibers and consequently affect the bioactivity and antimicrobial properties 
of the glass.  
A study from Lehtonen et al. tries to explain the change in mechanical characteristics of bioresorbable 
PLA/BG composite fibers in SBF100. They used a static PLA to BG ratio and three different compositions 
for the BG fibers for the tests. Also in their study, they found out that all of the composite fibers reach a 
stage where the degradation slows down but also that the steady state was directly related to the 
complete loss of the mechanical strength. However, the strongest composite they tested retained 
suitable flexural strength for load bearing capability for approximately 8-10 weeks which is plenty for 
clinical bone reconstruction and fixation purposes66.  
Another point worth further studying could be the creation of hybrid fiber structures. The 13-93 BG 
fibers could be bundled together with the 1-06 fibers and the reactivity of the implant surface could be 
more accurately engineered without having to invent a novel BG. A hybrid fiber bundle would have the 
characteristics from both fibers and it would allow for easy modification to achieve the desired 
properties by changing the ratios between the glasses. By using the two types of fibers together, it could 
be possible to control the speed of the bonding and surface reactivity. This way a more dynamic range 
of dissolution and reactivity characteristics could be acquired form the same materials.  
However, in the end, the material choices is only one part in designing the structural properties for the 
final implant. The volume fraction, directionality, and thickness of the fibers and also the implant design 
affect the structural rigidity, flexural properties, and durability49. In a study by Pirhonen et al., the 
volume fraction of the fibers affected the flexural strength and modulus of a PLA/13-93 BG composite 
significantly, and only the samples that had fiber content of 30% or more reached the strength of cortical 
bone101. The directional alignment of the fibers also has a big impact on the tensional strength of the 
implant. Unidirectional fibers increase the tensile strength while bidirectional alignment increase the 
flexural stiffness of the implant. A combination of unidirectional rods and bidirectional fibers in some 
areas can be used to further improve the stability of the implant under torsional and compressive 
32 
 
stresses16,66. The implant design allows the engineering of multiple properties by creating different 
shapes or surface structures to the final product. Different grooves, threading, surface coating, such as 
protein or BG coating, or surface roughening can be added to facilitate better fixation to the bone or 
accommodate to the natural shape of the bone structure49,102,103. By adding areas of different fiber 
alignment or volume fraction, the structural properties of the implant can be fine-tuned for each 
individual patient to create more personalized treatment and possibly reduce the risk of implant failure.  
Additionally, the synthetic biopolymers provide another beneficial feature for designing implants as 
they can be transformed into filaments and utilized in three-dimensional (3D) modelling systems such 
as fused deposition modelling (FDM). FDM allows the engineering of controllable porosity, complex 
micrometre-scale shapes, and easily reproducible consistent components, but it also enables creation of 
hybrid multi-layer structures from different polymers. FDM allows more freedom for the implant design 
and structural property engineering. For example, early 2000 Zein et al. designed porous scaffolds from 
PCL using the FDM technique104. They demonstrated the possibilities of FDM as a scaffold engineering 
technique by producing scaffold of controlled porosity and strength equivalent to typical porous 
scaffolds. In the follow up study, they proceeded to demonstrate successful cell attachment and 
proliferation of human fibroblast and osteoblast-like cells in in vitro environment105. In this study, the 
cells were able to proliferate and remained viable displaying good biocompatibility and safety of the 
scaffolds105. Following the positive results from the previous study, they attached primary human 
osteoprogenitor cells to the scaffolds and demonstrated the bone-bonding capability of the scaffolds in 
vivo in Balb C nude mice106.  
In the present study, FDM was utilized in the specimen scaffold production and the possibility of adding 
glass fibers to the printed structure was demonstrated. PLA was used as the polymer filament, and by 
first printing a base and then adding the fibers on top, it was possible to integrate the fibers to the 
structure when proceeding the print. The fibers would be sandwiched between the layers and attached 
to the structure. The overall thickness and also the variability of thicknesses of the manually pulled BG 
fibers caused some challenges in the attachment to the scaffold, but when using the much thinner E-
glass fibers, almost complete integration of the fibers was achieved. However, the attachment achieved 
by this method is completely mechanical and without a chemical connection. The possibility of sizing 
the fibers with a coupling agent to also reach a chemical bond between the fibers and the PLA should be 
further investigated, since sizing has been shown to increase the mechanical properties of BG/PLA 
composites100.  
Another fully computerized scaffolding method that could be utilized is embroidery69. With embroidery, 
more advanced and complex fiber alignment can be achieved. Also, polymer and BG fibers could be 
intertwined more closely for homogenous structure. Solely woven meshes are flexible and stretchable, 
and if load bearing is needed, the mesh could be coated with varying polymers to achieve rigidity. 
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Embroidery has been successfully utilized with biodegradable polymers and BG coatings70,71,107, 
however BG fibers have yet to be used with this technique. Embroidery provides an attractive option 
for implant production, since it is fast, computerized, reproducible, and versatile technique which is still 
largely underutilized.  
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5. Conclusions  
 
Glass fibers were pulled from three bioactive glass compositions to evaluate their bioactivity and 
usability in a novel load bearing composite material. As a result, the 1-06 fibers were considered to have 
medium bioactivity but the 13-93 and the 18-06 fibers were nonreactive in the SBF testing. However, 
the glass compositions of the fibers were heavily altered from the intended composition probably due 
to the original glass being phase separated or improperly homogenized, or the fiber pulling 
methodology affected the original composition. Therefore, the evaluation of the usability of these fibers 
for designing implants on the basis of this study remains inconclusive. Nevertheless, the important 
characteristics, properties, and material choices for a proper load bearing implant design were 
identified through literature search. Both isomers of PLA and PGL were evaluated to be suitable for the 
polymer component, and at least 13-93 is suitable for bioactive glass fiber component. However, a lack 
of proper studies assessing the compositional dependence of the different components on the 
mechanical and bioactive properties of biodegradable composites limited the ability to make more 
accurate estimations of the optimal materials. The optimal compositional range for PLA D/L ratio, PLA 
to PGA ratio, BG fiber fraction, fiber alignment, and BG composition in a composite material is not known. 
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